Under the organization of the European Society of Hyperthermic Oncology, the study was conducted in 9 centers located in Germany, Norway, Austria, and the United States using the BSD-2000 Deep Regional Hyperthermia System. This study enrolled 365 soft tissue sarcoma patients (18-70 years old) that were matched and entered into a double-blind study. One group received neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide [CT] treatment and the other group received the same chemotherapy along with a course of hyperthermia [HT].
For non-clinicians, we have done our best to provide the salient points in the above info-graphic. The full article can be found on the JAMA website here.
We feel that the results are astonishing. The HEADLINE:chemotherapy plus hyperthermia equals better results and extended life. #heatmatters
In our efforts to bring hyperthermia cancer treatment to the world, we are welcoming three new distribution, sales, and service companies covering 13 countries.
MedVision, a division of SADITA Holdings Group, is well known in the areas of cardiology, cardiac surgery, and peripheral intervention products. The company will be representing Pyrexar Medical in their home country of Kuwait, as well as Qatar, Bahrain, Saudi Arabia, Lebanon, Jordan, Egypt, UAE, Oman, Iraq, & Iran. This represents a significant expansion in the Middle East for Pyrexar, and we are looking forward to growing with them.
Tema Sinergie is based in Faenza, Italy, in the coastal province of Ravenna. The company's motto is "high tech, high care," and they have certainly been living up to that vision. Tema specializes in nuclear medicine, radiotherapy, uro-oncology, barrier solution technology, and medical physics. The group has been serving the country's need for medical products for over 30 years. Hyperthermia is an excellent extension of their product line, and we are excited to have them on our team.
Meyra Medicine and Health Products will be bringing Pyrexar Medical's hyperthermia product line to Turkey. Meyra, which translates to "shining star," is headquartered outside the coastal city of Izmir in the town of Kemalpasa, Turkey. In addition to sales and service support of hyperthermia, the company is also involved in ultrasound imaging products and proton therapy systems. Turkey is an emerging market economy with a healthy medical technology sector.
Please join us in welcoming our new members to the Pyrexar team.
A friendly reminder that the main Hyperthermia conference events in the US and Europe, STM and ESHO, are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.
The 35th Annual Meeting of the Society for Thermal Medicine and the 32nd Annual Meeting of the European Society for Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.
Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.
Who Should Attend?
Researchers in the field of thermal oncology
Clinicians, new to the field, who would like to talk with experts
Clinicians who want to expand their thermal oncology program
Medical Students that want to understand how hyperthermia may impact the future of medicine.
Pyrexar Distributors who want to expand their working knowledge of hyperthermia
A few facts that I learned during my visit to Kuwait; 1) gas is the fifth cheapest in the world, 2) the temperature can get hot enough to melt your tires, and 3) the region has excellent healthcare resources.
A local distributor, MedVision, is looking to bring hyperthermia to Kuwait and the surrounding region. MedVision, a division of SADITA Holdings Group, is considered one of the fast-growing companies in this field. Established in 2010, they are considered the market leaders in the territory, representing well-known companies in cardiology, cardiac surgery, and peripheral intervention.
Physicians gathered at the Kuwait Cancer Center to learn about advancements in hyperthermia. In addition to Mark Falkowski's Pyrexar's product overview presentation, MedVision invited hyperthermia expert and Director of the division of Translational Radiation Sciences at the University of Maryland School of Medicine, Dr. Zeljko Vujaskovic.
Ali Rabie, Senior Product Specialist, MedVision | Mark Falkowski, CEO - Pyrexar Medical | Ahmed El Ghamry, Business Unit Manager, MedVision
MedVision Headquarters, Safat, Kuwait
Dr. Zeljko Vujaskovic., Director of Translational Radiation Sciences at the University of Maryland School of Medicine
Oncologist gather at Kuwait Cancer Center to hear how hyperthermia can assist them in the treatment of cancer
Dr. Vujaskovic has published more than 150 articles and book chapters on radiation therapy, radiation injury, and hyperthermia topics. He has directed national and international research collaborations and is an active participant in cooperative group trials. He maintains a busy clinical practice, with a focus on advanced treatment approaches in prostate cancer. His presentation, “Principles of Hyperthermia in Cancer Treatment,” was well received. "The more we can get oncologist engaged, the greater the chance hyperthermia will return to its place as a pillar of cancer treatment."
We are in negotiations with MedVision to become an authorized distributor for Kuwait with expansion into Qatar, Bahrain, Saudi Arabia, Lebanon, Jordan, Egypt, UAE, Oman, Iraq, & Iran.
A reminder that he ORR (Oncoradiology, Radiology, and Radiotherapy) Congress will be held in Moscow, Russia, at the Holiday Inn from February 16-17, 2018. Representing Pyrexar Medical's hyperthermia product line will be our distributor Sennewald Medizintechnik, GmbH.
The main goal of the conference is to provide a platform for radiodiagnosticians, radiotherapists, and medical physicists for education, ideas and experience exchange, discussion of actual issues, and professional communication. For the first time traditional conferences such as “Radiodiagnosis Standards in Oncology,” “Radiotherapy in Oncology,” “Medical Physics in Oncology,” “Interventional Radiology in Oncology,” “Radionuclide Therapy in Oncology” and the conference with international participation “PET in Oncology” will be considered within the same event. Also, for the first time, the conference “Ultrasonic Diagnosis in Oncology,” dedicated to the memory of Professor S. Balter will be performed, and discussion site for fundamental and theoretical problems in radiobiology will be provided.
I just returned from a five day trip to India at the invitation of our distributor Kirloskar Technologies (KTPL). A special thanks to the planning and support of Mr. Ketan Desai, President of the Oncology Business at KTPL, for arranging the site visits and taking such good care of us. India is a huge market and can play an essential role in the growth of Pyrexar. To put the Indian market into perspective, the country represents just under 18% of the world population (1.34 billion population) packed into a landmass 1/3 the size of the US (323 million people). Treating the nation's cancer patients is a severe challenge.
Sasi Sekhar, KTPL Service Manager | Ketan Desai, President Oncology Business, KTPL | Dr. Geeta S Narayanan, Vydehi Institute | Mark Falkowski, CEO, Pyrexar Medical | Dr. Lokesh Viswanath | Dr. R. Vinaykumar
Mr. Sayan Bhattacharya | Dr. Jigna Bhattacharya, Assoc. Professor, Gujarat Cancer & Research Institute | Mark Falkowski, CEO, Pyrexar Medical | Ketan Desai, President Oncology Business, KTPL
Mark Falkowski, CEO, Pyrexar Medical | Dr. Nagraj Huilgol, Chief Radiation Oncologist, Nanavati Super Specialty Hospital | Ketan Desai, President Oncology Business, KTPL
Dr. Huilgol currently practicing at Nanavati. "Don't let the quaint exterior fool you, this is as modern a facility as any I have visited in the US" says Mark Falkowski
The journey took us down the western coast of India, where we visited with several essential hospitals targeted to introduce our radiative hyperthermia product line to the country. From Ahmedabad in the Northwestern state of Gujarat to the coastal city of Mumbai in Maharashtra, to the southern city of Bangalore in Karnataka. Information was well received, but they all asked the same question, "Where have you been." That question is a little challenging to answer as our products are well established in European nations, in the US, China, and proliferating on the Korean peninsula.
Where have you been? Why isn't Pyrexar in India?
Pyrexar has seen tremendous growth in the last three years. The regulatory requirements to enter each new country are rigorous, and we have been working quickly to bring proven hyperthermia treatment to the world. As we start filling the void, lesser technologies are pushed aside and replaced. The simple truth to why we are not active in India is that we did not have reliable distribution partners, until now. Kirloskar Technologies has the technical understanding, product depth and reach, and a service team that can handle our product line. With this partnership in place, it is possible to bring our systems to market in India.
One of the highlights of the trip was my meeting with Dr. Nagraj Huilgol. As you may know, Dr. Huilgol is a hyperthermia advocate and researcher with more than 100 publications in national and international journals. He was lead researcher in phase III clinical study on head and neck cancer using capacitive hyperthermia. His CV includes Chief Editor of the Journal of Cancer Research and Therapeutics (JCRT) and a member of editorial boards of the Indian Journal of Cancer, Indian Journal of Head and Neck Cancer, International Journal of Hyperthermia and the official journal of ASHO, ESHO, and NAHO. Having this well-known hyperthermia expert as a luminary will help usher hyperthermia into India.
We are proud to announce the signing of Finggal Link Co. Ltd, headquartered in Tokyo, as our new distributor in Japan. Through the combined efforts of Mr. Masaaki Inoue of Advanced Medical and the regulatory group at Finggal Link, we hope to reinvigorate the product line in Japan.
In the 1980s and 1990s, there were approximately twenty BSD-1000 units installed in Japan. The BSD-1000 is the predecessor to the products we have today. In 1993, the sales distributor for Japan was dissolved, leaving a product registration void that was never re-established. With this new effort, we hope to introduce the new Pyrexar product line and revive the use of hyperthermia for the treatment of cancer in Japan.
Masaaki Nagone-CEO, Finggal Link; Mark Falkowski - CEO, Pyrexar Medical; Kenji Hirayama - Director, Int'l Affairs and RA/QA, Finggal Link Dr. Tetsuya Furukawa - Director, Medical Division, at Finggal Link, will head the clinical introduction efforts at major hospitals throughout the country. A special thanks to Dr. Hayes and the thermal oncology team at Gamma West Cancer Services in Salt Lake City for allowing Dr. Furukawa to observe a Head and Neck Brachytherapy and Hyperthermia treatment at the St. Mark's location. Gamma West is an excellent asset to the medical community in Utah, and throughout the intermountain region, providing lifesaving and life-changing procedures for cancer patients.
Masakki Innoue - Advanced Medical Systems; Dr. John Hayes - Gamma West Cancer Services; Paul Turner - Pyrexar Medical; Dr. Tetsuya Furukawa - Finggal Link
We want to acknowledge all the speakers for their participation at the First International Conference of the Polish Society for Hyperthermic Oncology. It was a fantastic event. Special thanks to the dedicated team at HT systems for creating such a dynamic conference and for re-energizing hyperthermia in Poland. And to the co-sponsors of the event for their support of the meeting. Pyrexar Medical strives to support hyperthermia (the treatment of cancer with heat) education and research around the globe.
Distribution Partner HT Systems
Dariusz Droś, CEO of HT Systems and Mark Falkowski, CEO of Pyrexar Medical
BSD-2000 Scale Model
HT Systems commissioned a 1/3 scale model of the BSD-2000 Sigma Base with the Sigma Ellipse Applicator
HT Systems is the exclusive distributor of Pyrexar Medical Hyperthermia Systems in Poland
Meeting Well Attended
A large group of researchers and clinicians attended the event at the Hotel Rezydencja Luxury, Piekary Slaskie, Poland
The lectures were professionally recorded and are in the editing process. The PTHO has started a Youtube Channel, which will be hosting the video presentations of the speakers listed below.
Prof. Niloy R. Datta, MD, DNB, CCST (CH)
"Overview of meta-analysis clinical trials in head neck cancers / recurrent breast tumors / locally advanced cancer cervix." [Language: English]
Senior Consultant and Head, Radiation Oncology Research Programme, Centre of Radiation Oncology KSA-KSB, Kantonsspital Aarau AG, Aarau, Switzerland
Dr. Sc. Hana Dobsicek Trefna, Ph.D. (S)
"Quality assurance in hyperthermia treatments." [Lecture: English]
Assistant professor in the Biomedical electromagnetics research group and an expert in systems and focusing algorithms for microwave hyperthermia treatment of deep-seated tumors. Her work aims at the clinical introduction of hyperthermia in Sweden, developing a UWB hyperthermia system for the treatment of Head and Neck tumors and exploring the possibility of hyperthermia treatment of brain tumors in children.
Dr. med. Boris Hübenthal, MD, Ph.D. (CH)
"Case Reports from the Center of Integrative Oncology ZIO Zurich" [Language: Polish]
Medical Director of the Center of Integrative Oncology ZIO in Zürich Switzerland, Chairman of the European Society for integrative oncology ESIO eV. Principle investigator of the database project www.bestcase-oncology.com
Prof. Rolf Issels, MD, Ph.D. (D)
"Up-date on clinical trials combining regional hyperthermia with chemotherapy" presented at the PTHO Conference " [Language: English]
Head of the Clinical Cooperation Group Hyperthermia Researcher at the Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Dr. Jacek Kabut, MD, Ph.D. (PL)
"The treatment of bladder cancer combined with regional hyperthermia - case report" [Language: Polish]
Specialist of Internal Medicine and Oncology. Chief Assistant of the Oncology Department in the Regional Specialist Hospital in Rybnik. Oncology consultant in the Regional Hospital of Pulmonary Diseases in Wodzisław-Śląski Wilchwach. Member of the Polish Society for Clinical Oncology, Polish Society for Experimental and Clinical Immunology and of Polish Society for Hyperthermic Oncology.
Dr. Dorota Kazberuk, MD (PL)
"Deep tissue hyperthermia in oncological gynecology in Białystok Cancer Center." [Language: Polish]
Radiation Oncologist in the Radiation and Brachytherapy Department and Brachytherapy Coordinator of the Białystok Cancer Centre. Member of the supervisory committee of the Polish Brachytherapy Society (PTB). Regional Branch President of the Polish Oncology Society of Podlasie.
Prof. Wiesław Kozak, Ph.D. (PL)
"Fever Biology" [language: Polish]
Full Professor at the Nicolaus Copernicus University in Toruń, Poland, former Dean of Biology and Environmental Sciences, Head of Immunology Department
Dr. Andrzej Kukiełka, MD, Ph.D. (PL)
"Rescue brachytherapy combined with interstitial hyperthermia in local relapse of prostate cancer after radical radiation therapy - prospective study phase II - current state of research." [Language: Polish; Slides: English]
Radiation Oncologist in NU-MED Cancer Diagnostics and Therapy Centre in Zamość Member of European Society of Hyperthermic Oncology (ESHO) Member of the Review Panel of the Polish Brachytherapy Society (PTB)
Prof. Urszula Mazurek, MD, Ph.D. (PL)
"Heat shock proteins in hyperthermia applied in oncology." [Language: Polish; Slides: English]
Head of Department of Molecular Biology at the Silesian University of Medicine, Member of Scientific Committee in the Biotechnology Center of the Silesian University of Technology.
Dr. Med. Michal Niksa
"Operation of the BSD-2000. Experiences made in Cancer Centre of Białystok". [language: Polish]
A member of the Department of Radiotherapy with the Brachytherapy Department of the Białystok Cancer Center
Dr. Markus Notter, MD, Ph.D. (CH)
"Low dose re-irradiation & hyperthermia in extended local recurrent breast cancer: perspectives and challenges." [Language: English]
Radiation oncologist in the Lindenhofspital in Bern (CH), vice-president of the Berne Foundation against Cancer (Ligue Bernoise Contre le Cancer), member of the board of the Swiss Cancer League.
Prof. Elisabeth Repasky, MD, Ph.D. (USA)
"Temperature Matters: Chasing an elusive evidence-based rationale for hyperthermia in the cancer clinic." [Language: English]
Professor of Oncology, William Huebsch Professor of Immunology and Program Leader for the Cell Stress and Biophysical Therapies Program at Roswell Park Cancer Institute in Buffalo, NY.
Dr. Wacław Śmiertka, MD, Ph.D. (PL)
"Recommendations of PTHO for the use of hyperthermia in selected cancer diseases." [Language: Polish; Slides: English]
Gynecologic Oncologist in Warsaw Cancer Institute
Dr. Bartosz Urbański, MD, Ph.D. (PL)
"The oncologic hyperthermia" presented during the conference of PTHO." [Language: Polish]
Radiation Oncologist in Great-Poland Cancer Institute, Poznan
Dr. Jacoba van der Zee, Ph.D. (NL)
"Results of randomized trials comparing treatments with or without hyperthermia." [Language: English]
Researcher in the field of Hyperthermia at the Dept. of Radiation Oncology, Erasmus University Rotterdam, Rotterdam
Prof. Gerard C. van Rhoon, Ph.D., (NL)
"Current Technology for Hyperthermia Treatment" [Language: English]
Professor in Erasmus MC Cancer Institute, head of Hyperthermia Unit, president of the European Society for Hyperthermic Oncology (ESHO)
Dr. rer. nat. Alexander von Ardenne, Dipl.-Phys. (D)
"Non-oncological hyperthermia and a new immunological road to attack cancer" presented during the conference of PTHO." [Language: English]
Head of the "Von Ardenne Institute of Applied Medical Research GmbH"
Prof. Zeljko Vujaskovic, MD, Ph.D. (USA)
"Hyperthermia and Immunotherapy in Cancer Treatment: Rational and Clinical Directions" [Language: English]
Professor at the University of Maryland School of Medicine, USA. Head of the Division of Translational Radiation Sciences in the Department of Radiation Oncology
Prof. Holger Wehner, MD, Ph.D. (D)
"Extreme whole-body hyperthermia: risks and opportunities." [Language: English]
President of German Hyperthermia Society. Medical director in the Gisunt Klinik - Integrative Medicine and International Hyperthermia Centre. Specialist for hyperthermia for 30 years.
We are excited to announce the commissioning of a BSD-2000 3D/MR "Universal" System at Grosshardern University Hospital in Munich, Germany.
LMU (Ludwig Maximilians University of Munich in Großhadern) has been a pioneer in cancer treatment with hyperthermia. The hospital has treated over 15,000 patient treatments with hyperthermia, many of them with Soft Tissue Sarcoma tumors. This facility was part of a phase III clinical study that illuminated the long-term survival benefits of adding hyperthermia to chemotherapy. LMU is also at the center of the HEAT (Hyperthermia European Adjuvant Trial) study, a randomized, dual-arm trial for pancreatic cancer using chemotherapy plus hyperthermia.
The BSD-2000 3D/MR uses MR imaging to visualize temperature in the treatment area. MR images are taken during the hyperthermia treatment, and proprietary software creates a three-dimensional (non-diagnostic) representation of the heating zone in the body. With this information, the operator can easily adjust the heating zone in 3 dimensions to ensure that the tumor area receives the maximum thermal dose. Above is an excellent product video produced by Sennewald Medizintechnik GmbH, the innovators of the SigmaVision software and Pyrexar’s distributor in Germany.
The Sigma Eye MR applicator uses the existing MR patient support table and can be removed and stored when not in use, leaving the MR free for general imaging. The complete system package includes a Dodek 12-channel RF amplifier (positioned in the equipment room), the Sigma Eye MR applicator, a water circulation system that provides temperature-controlled deionized water to the applicator bolus (seen in blue), an 8-channel motor-controlled temperature box (used to verify thermal accuracy during treatment), and a computer system with control software.
The BSD-2000 3D/MR fits most 1.5 Tesla, 60cm bore (or greater) MRI systems on the market. Our system runs at 100MHz, providing deep regional hyperthermia to any depth in the body. The applicator is capable of treating up to 95 percentile patient size based on available world data.
The technology used in capacitive hyperthermia has changed very little since its invention in 1916, and its future is in question. The advent of computerized controls and motorized applicator arm has done little to change the way energy flows between electrodes, nor has it improved treatment outcomes. The replacement of wet cotton rags, for the current connection, with a water bolus, is probably the only real advancement forward of this aging technology. Issues like the inability to steer or shape the heating zone, the failure to increase focus or accuracy, may never be solved.
Q: What are three things Capacitive Hyperthermia and the Pop-up Toaster have in common? (answer at the bottom)
The future of hyperthermia is in Phased Array Radio Frequency. Phased Array RF is a superior heating method, according to a recent study, “A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia” by Kok and Crezee. The ability to focus, steer, and size the heating zone, monitor and maintain zone temperature, use numerical modeling for treatment planning, is all part of this advancing technology. There is a reason that there are so few positive phase III studies using capacitive systems; the heating method is challenging to quantify. The introduction of non-invasive thermometry using MRI has created a new interest in hyperthermia. These advancements are giving researchers new tools and clinicians more resources to help cancer patients. The chances for a positive cancer outcome merely is getting better.
Capacitive Heating has several flaws.
Fat layer power absorption. Capacitive heating applies ten times more power per cubic centimeter in surface fat than in tissues below the fat layer, such as tumors. This leads to significant patient discomfort and pain during treatments. The power absorbed within a 1 cm surface fat layer is equivalent to the same power distributed over the next 10 cm of tissue. If you administered 200 watts of power, 100 watts would be stuck in the fat layer generating a hot spot; the remainder of the energy ( only 10 watts per cm) is spread over the next 10 cm in depth. Certainly not enough energy to heat a tumor. How many of your patients have more than 1 cm fat layer? Check out the world obesity figures.
Field Shape. It is complicated to create an accurate treatment plan when you can not control field shape. Capacitive RF heating fields diverge as they penetrate in the body unless the high water content pathways are constrained by low water tissues such as bone structures of the pelvis. The only control of the shape of the heating pattern is by the placement and sizes of the electrodes used.
No Future as an Image-Guided Therapy. Although temperature sensors are available as an option (although rarely used) on capacitive hyperthermia systems, there is no ability to respond to the distribution of heating during a treatment. The operator can change the amplitude of the RF power and the temperature of the electrode cooling bolus. This limits the possible benefit of invasive or non-invasive thermometry methods. Although one could build a system that would fit inside an MRI, the operator would only be able to turn the power up or down. There would be no ability to guide the treatment zone to the target area. It would be like driving a car that only had an accelerator, but no steering wheel.
Is your product Hyperthermia? In the U.S., the term "bait and switch" refers to companies that attract you with features and benefits of one product only to try to sell you an inferior product when you arrive. One manufacturer of capacitive systems does such a poor job delivering a thermal dose that they must “bait” the customer with well-known hyperthermia studies only to “switch” technologies with unproven claims that fractal frequency kills cancer cells. Thirty years of hyperthermia research, 17 phase III clinical studies, and hundreds of peer-reviewed clinical studies agree the active effects are due to temperature, not frequency modulation.
When presenting Pyrexar technology to a customer, you are offering a future.
Statement: Phased Array Radio Frequency systems are generally more expensive. Reason: The axiom "you get what you pay for" plays well here. You are paying for superior equipment proven by years of published data and tens of thousands of patient treatments.
Statement: Phased Array Radio Frequency systems require more training to treat patients. Reason: We wish it could be a push of a button like a chest X-ray, but practical results require proper treatment planning and simulation, similar to a Linear Accelerator, for vastly superior patient outcomes.
Statement: Phased Array Radio Frequency has a future. Reason: Continuing research and the advancement of software, a simple update can make your existing system work better and better.
Question: If you or your loved one was diagnosed with cancer, which technology would you choose? Maybe good enough, or the proven best.
The answer to the Quiz Question: They were both invented 100 years ago, the technology has advanced little in 100 years, and Capacitive Hyperthermia technology nowhere to go.
Pyrexar welcomed Dr. Joon Kim, Chief of the Medical Clinic at Oasis Medical Care Hospital, for a site visit in Salt Lake City, Utah. Dr. Kim specializes in treating cancer with hyperthermia. Accompanying the doctor was Pyrexar's South Korea distributors, Harris Maeng of Hanbeam Technologies and Michael Cha, CEO of Ivy-Lab. The group observed Dr. Hayes perform brachytherapy and hyperthermia on a recurrent ovarian tumor patient at the St. Mark's location of Gamma West Cancer Services. There is a lot of positive and innovative outcomes both inpatient recovery and reimbursement, which I will discuss in a future post.
Harris Maeng (Hanbeam), Dr. Joon Kim (Oasis), Mark Falkowski (Pyrexar), Michael Cha (Ivy Lab), Drew Wilkens (Pyrexar)
ASTRO 2017 Trade Show in San Diego
A jam-packed three days in San Diego for the 59th Annual American Society of Therapeutic Radiation Oncology Meeting. Attendance was approximately 11,000, and we had a great response at the booth. The president of Dalian Orientech (Pyrexar’s Mainland China distributor), Mrs. Shuzhi Wang, brought a large contingent of physicians for an in-booth presentation of the newly updated BSD-2000/3D/MR. Also, Dr. Zeljko Vujaskovic shared a presentation on the clinical benefits of hyperthermia in the treatment of cancer and how the University of Maryland School of Medicine has integrated thermal oncology in their practice. Other visitors included South Korea distributors, Hanbeam Technologies, along with their newest marketing and sales partner Ivy-Lab, Finggal Link from Japan, and Sennewald Medizintechnik representing Europe and Russia. The star of the show, as always, was "Virtual CTO" Paul Turner. Not only was he available on the show floor to share his vast knowledge in his autonomous robot form, but he was also available for selfies.
JCA - Japan Cancer Association
This year the BSD-500 returned to Japan. Hyperthermia has been a well-accepted therapy in Japan for the last three decades. From 1984-1992, eighteen BSD-500’s were shipped to the island nation. Soon after, the Japanese Government funded the development of their own Capacitive Hyperthermia system, the Thermotron RF. After a brief unveiling at the Japan Cancer Association Conference in Yokohama, and with the help of Dr. Taro Sirakawa of Tough Idenshi Meneki Clinic, the BSD-500 will now be available to treat patients once again.
In our last blog Taiwan Partners and Water, we introduced you to AMES Medical from Taiwan. The group was inadvertently labeled as representing South Korea. Our apologies to Stephen, Johnson, and Andy for the mistake.
Ames Medical Team - Andy Hsu, Johnson Chen, Mark Falkowski (Pyrexar), Steven Shih
We had two visits last week, one friendly and one not so friendly.
The very friendly visitor was from Ames Medical, our newest sales and marketing group in Taiwan. Steven, Johnson, and Andy spent the week with us for sales and technical training on the Pyrexar product line. They have some excellent ideas on how to penetrate the Taiwan market and have put together a well thought out strategic sales plan.
Andy Hsu, Johnson Chen, Mark Falkowski, Steven Shih
During the visit, Steven wanted to see what it felt like to be a patient in the BSD-2000, so we put him on the patient sling inside both the Sigma 60 and Sigma Ellipse applicator and filled the bolus with water. (we left the power off). He remarked that being surrounded by the bolus was both comfortable and comforting. He mentioned cancer patients in Taiwan were afraid to move around while receiving hyperthermia treatment. We hypothesize that may be a belief left over from the importance of not moving during radiotherapy. We assured him that the heat zone on the BSD-2000 was large enough that casual movement would not affect therapeutic outcomes.
On Friday, as we were about to send our visitors home, a water main under the building a few doors down broke. What started as a puddle, turned into a torrent and headed to our building. It was all hands on deck, including the Ames Team. We all grabbed brooms and created makeshift water dams and attempted to push the water out as fast as it came in. We managed to quickly get everything off the floor. After 2 hours, the fire department turned off the water and we started to put everything back together. We appreciate the help from our new sales partners, along with the enthusiasm they bring to hyperthermia and the treatment of cancer.
REMINDER: We will be exhibiting at ASTRO 2017 in San Diego starting this Sunday. Look for us at booth #646
This year the PTHO invited more than 20 speakers, prominent scientists, experts in hyperthermia, from many different countries. Besides polish speakers, you will have the opportunity to hear the lectures of guests from the USA, Holland, Switzerland, Germany, Russia, and China. The main topic of the Conference will cover hyperthermia trends in the treatment of cancer. The conference goal is to present the standard procedures of combining hyperthermia with radiation therapy, chemotherapy, and other systemic therapies. One of the sessions will be dedicated to the biology of fever and to the immunological effects of hyperthermia.
The conference will be held on October 20-21st, 2017, in Piekary Slaskie, Poland, at the beautiful and award-winning Hotel Rezydencja Luxury.
Who should go? If you are a thermal oncologist or someone looking to understand how hyperthermia can be used as part of a comprehensive cancer treatment program, this conference touches on all of the topics. Pyrexar will have on display its new BSD-2000 3D/MR applicator, which features live 3D non-invasive temperature mapping utilizing MRI guidance for accurate heat placement. A complete program is available on the PTHO website (www.konferencja2017.ptho.pl/programme)
Representing Pyrexar at the event will be CEO, Mark Falkowski, and our local distributor Darius Dros, and his team from HT Systems. Conference Admission and Hotel prices are extremely affordable, especially for the caliber of speakers and international contacts you will meet. Register before September 19th and save 25%. Registration and information are available on the PTHO website.
Pyrexar is proud to welcome Kirloskar Technologies to its distributor network. Kirloskar Technologies, popularly known as KTPL, is part of the 100-year-old, multi-billion dollar conglomerate, the Kirloskar Group.
Kirloskar has been a successful healthcare enterprise for more than two decades, offering a multi-disciplinary product portfolio catering to the fields of Cardiac Surgery, Interventional Radiology, Interventional Cardiology, Neurosurgery, Nuclear Medicine, Oncology, Radiography, Vascular Surgery, Minimal Invasive Surgery, and Plastic & Reconstructive Surgery.
According to cancerindex.org, more than 1 million people were diagnosed with cancer in India in 2012. Cancer death rates stand at 680,000 each year. The National Cancer Registry puts breast cancer as the most common cancer for women in India, with cervical cancer in second. It is estimated that for every two women newly diagnosed with breast cancer, one dies. Every 8 minutes, a woman dies of cervical cancer. The good news is that hyperthermia is a highly effective adjunct treatment of both breast cancer and cervical cancers.
India represents a significant expansion into Asia for Pyrexar. India accounts for one-sixth of the world population, ten times greater than the population of the United States. Kirloskar believes that Pyrexar’s hyperthermia line is an excellent companion to their radiotherapy product offering, and the therapy will play a necessary role treatment of cancer in the country. There are some real advocates for hyperthermia in the region. We believe these influencers can help bring awareness and acceptance of the technology to cancer centers throughout India.
Healthcare spending in China has been increasing over the past few years, and China is now the second-largest healthcare market in the world. Pyrexar has been represented in China by our trading partner Orientech Dalian for the last ten years. Ever since the name and address change from BSD Medical to Pyrexar, we have been working with the Chinese regulatory agencies to re-register the product for export to the country. Bureaucracy can take its toll on market presence, especially in the growing field of hyperthermia.
Mrs. Wang, President (Orientech); Bob Depalma, VP Regulatory (Pyrexar); Dr. Wu Dengbin, VP Oncology Ansteel; Mark Falkowski, CEO (Pyrexar); Dr. Zhou Tong (Ansteel); Dr. Zhu Xu (Ansteel)
So we took a trip to China to review our regulatory progress and meet with potential customers for our hyperthermia products. As we have experienced in the past, Orientech is a very generous host, treating us very well on each leg of our journey. After some internal discussions with our distributors, we believe we have a direction to alleviate the regulatory blocks, so products will again be available in China.
Orientech invited us to present our hyperthermia line to key prospects in the area. The first stop was the Ansteel Group Hospital, a large facility in the Tiedong District of Anshan in the Liaoning Province. The Ansteel Group facility houses center for Cancer, Genetic Detection, Immunotherapy, and Radiation Oncology. Our next stop was Dalian Municipal Central Hospital in the Shahekou District of Dalian in the Liaoning Province. Dalian Municipal has received many accolades, including “top 20 best service hospitals” and “most reliable hospital in the province.”
After successfully met presentations, not only were the hospitals very excited and receptive about adding hyperthermia to their cancer treatment services, but they preferred the newly updated, top of the line, Image-Guided Thermal System, the BSD-2000 3D/MR. According to Mrs. Wang, president of Oreintech, there are more than half a dozen hospitals in the region looking at the new MRI based system. Now I feel a bit embarrassed teasing the new product without supporting product information. Our first commercial installation of the newly updated product is being signed off this week in Munich, Germany, and we will bring you more details very soon.